Tyrokin 400 mg (Tablet)

Unit Price: ৳ 300.00 (1 x 10: ৳ 3,000.00)

Strip Price: ৳ 3,000.00

Medicine Details

Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase
Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy
Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements
Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown
Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR a fusion kinase
Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans
Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors
Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST

Small molecule protein-tyrosine kinase inhibitor
Inhibits Bcr-Abl tyrosine kinase (TK) and several receptor TKs: Kit, DDR1, DDR2, CSF-1R, PDGFR-alpha, PDGFR-beta
Well-absorbed after oral administration
Mean absolute bioavailability is 98%
Metabolized by CYP3A4 enzyme
Elimination is predominately in the feces, mostly as metabolites
Plasma protein binding of N-demethylated metabolite CGP74588
Plasma half-lives of Imatinib and its major active metabolite

Concomitant administration of Tyrokin and strong CYP3A4 inducers may reduce total exposure of imatinib
Concomitant administration of Tyrokin and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase
Grapefruit juice may also increase plasma concentrations of imatinib
Use caution when administering Tyrokin with CYP3A4 substrates that have a narrow therapeutic window
Use caution when administering Tyrokin with CYP2D6 substrates that have a narrow therapeutic window

Women of childbearing potential must use effective contraception during treatment and for at least 15 days after stopping treatment
Limited data on the use of imatinib in pregnant women
Potential risk for the fetus is unknown
Imatinib should not be used during pregnancy unless clearly necessary
Women should not breast-feed during treatment and for at least 15 days after stopping treatment
Studies on patients receiving Imatinib and its effect on fertility and gametogenesis have not been performed

Edema and severe fluid retention have occurred
Cytopenias, particularly anemia, neutropenia, and thrombocytopenia, have occurred
Severe congestive heart failure and left ventricular dysfunction have been reported
Severe hepatotoxicity may occur
Grade 3/4 hemorrhage has been reported
Cardiogenic shock/left ventricular dysfunction has been associated with the initiation of Tyrokin
Bullous dermatologic reactions have been reported with the use of Tyrokin
Hypothyroidism has been reported in patients undergoing levothyroxine replacement
Fetal harm can occur when administered to a pregnant woman
Growth retardation occurring in children and pre-adolescents receiving Tyrokin has been reported
Tumor Lysis Syndrome monitoring is recommended
Reports of motor vehicle accidents have been received in patients receiving Tyrokin
Renal Toxicity evaluation is recommended

Targeted Cancer Therapy, Tyrosine Kinase Inhibitor

Store below 30°C, in a cool and dry place. Keep away from light. Keep out of the reach of children